|
medpundit |
||
 |
 |
|
Tuesday, November 15, 2005Is it a good drug, or a bad drug? The stock market apparently thinks the latter. Here are the details of the study: In a separate trial involving its cholesterol drug TriCor, the drug failed to make a statistically significant difference in reducing non-fatal heart attacks or heart related deaths among diabetic patients, Abbott said. The drug did show benefits in reducing other cardiovascular deaths, strokes and the need for bypass surgeries. The study involved nearly 9,800 diabetic patients and represented the largest study ever examining the effect of a cholesterol-lowering medicine on cardiovascular illnesses among diabetics, Abbott said. The results could lead to increased use of TriCor in diabetic patients and as a combination therapy with statin drugs, such as Lipitor, Nalbone said. It doesn't influence heart attacks deaths, but it does reduce stroke deaths (in diabetics), though by what margin we aren't told. Although we should be told that, given its hefty monthly price tag. ASIDE: One of the most annoying things about this drug, effectiveness aside, is that the manufacturer keeps changing the dosage. It seems like every twelve months or so I'm getting calls from pharmacies saying the pill the patient is taking is no longer available at that dosage. posted by Sydney on 11/15/2005 07:43:00 AM 0 comments 0 Comments: |
|
